Contact

Dr. Stefanie Koristka
Radioimmunology
s.koristkaAthzdr.de
Phone: +49 351 458 6526

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - +49 351 458 2101, 2060, 3170, +49 172 694 8424
Fax: +49 351 260 - 3232

Modulation of tumor microenvironment via manipulation with Tregs or check point inhibitors

Treg Supression

Especially the immunosuppressive milieu of solid tumors hampers immunotherapeutic approaches of malignant diseases. As a result, many tumor cells show an up-regulation of inhibitory receptors/ligands (check point) and malign transformed tissues are infiltrated with immunosuppressive cells among them notably regulatory T cells (Tregs). The same technics like bsAbs, CARs and UniCARs (see also Antibody-based and Cellular Immunotherapeutics) can be also used in the context of Tregs. We aim to investigate, whether the manipulation of Tregs by these tools alone or in combination with check point inhibitors can result in modulation of the immunosuppressive tumor milieu. Vice versa Tregs can be also used therapeutically in the context of cellular tumor therapies, e.g. in case of bone marrow transplantations that are accompanied by GvHD (Graft-versus-Host Disease) reactions. Thereby, it became evident that antigen-specific Tregs should be superior to polyclonal Tregs.

References: Treg-CAR-BiTE

Contact

Dr. Stefanie Koristka
Radioimmunology
s.koristkaAthzdr.de
Phone: +49 351 458 6526

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - +49 351 458 2101, 2060, 3170, +49 172 694 8424
Fax: +49 351 260 - 3232